Petros Pharmaceuticals (NASDAQ:PTPI) Shares Down 8.6%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) fell 8.6% during mid-day trading on Wednesday . The stock traded as low as $0.42 and last traded at $0.44. 448,521 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 754,254 shares. The stock had previously closed at $0.48.

Petros Pharmaceuticals Trading Down 8.6 %

The company has a quick ratio of 1.46, a current ratio of 1.60 and a debt-to-equity ratio of 0.66. The firm has a market cap of $3.07 million, a P/E ratio of -0.06 and a beta of 2.13. The company’s 50 day simple moving average is $0.57 and its 200-day simple moving average is $1.07.

Petros Pharmaceuticals (NASDAQ:PTPI) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($2.05) earnings per share (EPS) for the quarter. The firm had revenue of $1.39 million during the quarter. Petros Pharmaceuticals had a negative return on equity of 102.32% and a negative net margin of 181.87%.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).